The role of intestinal microbiota and permeability in inflammation and in the pathogenesis of morbid obesity

The role of intestinal microbiota and permeability in inflammation and in the pathogenesis of morbid obesity - Intestinal integrity and microbiota in patients with morbid obesity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32675

Enrollment

Registered

2009-12-21

Start date

2010-06-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Research population: * BMI >35 kg/m2 * age 18-60 years;Healthy Controls: * BMI 20-25 * age 18-60 years

Exclusion criteria

Exclusion criteria: * Age 60 years * Diabetes Mellitus type I * Inflammatory diseases such as auto-immune diseases (due to a higher inflammatory profile) * Degenerative disase * Alcohol or drug abuse * use of corticosteroids and / or prednisolone (confounding effect on inflammatory status)

Design outcomes

Primary

Measure	Time frame
* BMI, hip/waist ratio * Intestinal permeability: excretion of orally administerd sugars in urine * Intestinale damage: plasma markers (IFABP, ILBP and LFABP) * Plasma inflammation markers (CRP, IL-6, TNF-, MPO, PAI-1, adiponectin, leptin, endotoxin, Endocab) Insulin resistence (glucose, insulin, HOMA-IR, HbA1c, lipids)	—

Countries

Netherlands

Outcome results